Tracking the turning point in Alzheimer's disease.

Key Points

• To identify blood biomarkers indicative of the transition from amyloid to tau pathology in Alzheimer's disease.
• Utilized a blood biomarker to track pathology transitions.
• Investigated mechanistic changes in Alzheimer's disease.
• Analyzed the relationship between amyloid and tau pathology.
• Identified a significant mechanistic shift indicated by the blood biomarker.
• Revealed a clear transition timeline from amyloid to tau pathology in Alzheimer's disease.